R&D AI can help us build a new, more precise, antibiotic pipelin... AI has begun to influence early-stage antibiotic discovery by identifying novel antibacterial compounds that are difficult to uncover traditionally.
News EU invests €30m to fight antimicrobial resistance The EU has pledged €30m in funding for countermeasures to antimicrobial resistance, earmarked for the discovery and development of new antibacterials.
R&D Europe has the tools to fight superbugs. Let’s use them. Data shows countries are off track – increasing the risk of profound health and economic consequences from AMR. Medical technologies can help.
R&D Sponsored Why conditions like UTI call for new antibiotics Exploring the growing threat of UTIs, the need for new antibiotics, and GSK’s role in advancing targeted treatments.
R&D Why I'm focused on the trillion-dollar AMR crisis everyone's... AMR demands sustained commitment beyond conventional market incentives.
R&D When is the superbug message going to bite? As existing antibiotics become less effective, we edge closer to a future where routine infections & minor injuries could once again become high risk.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.